Is Lexicon Pharmaceuticals, Inc. (LXRX) a Buy, Sell, or Hold?
NASDAQ : LXRX
Lexicon Pharmaceuticals, Inc. — Institutional Ownership
$2.23 USD
-$0.06 (-2.62%)
- Volume
- 2.96M
- Average Volume
- 3.38M
- Market Capitalization
- $990.56M
- P/E Ratio
- -31.23
- Dividend Yield
- 0.00%
- Price Target
- $6.00
- Year High
- $2.68
- Year Low
- $1.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $18.79
Institutional Ownership Summary
Institutional Ownership %
0.07%
Investors Holding
13
change: -128 | last: 141
Increased Positions
5
change: -66 | last: 71
Reduced Positions
2
change: -25 | last: 27
New Positions
4
change: -27 | last: 31
Sold Positions
126
change: 107 | last: 19
Total Calls
-
Total Puts
-
Put-Call Ratio
0.00
change: -8.29 | last: 0.0829
Total Invested
626.4K
Beneficial Ownership Filings
| Filing Date | Reporting Person | Amount Beneficially Owned | % of Class |
|---|---|---|---|
| 2026-05-08 | Raymond Debbane | 51.88M | 11.70% |
| 2026-05-08 | Amaury Wittouck | 175.16M | 39.40% |
| 2026-05-08 | Stichting Administratiekantoor Westend | 175.16M | 39.40% |
| 2026-05-08 | Avicenna Life Sci Master GP LLC | 1.54M | 0.30% |
| 2026-05-08 | Avicenna Life Sci Master Fund LP | 1.54M | 0.30% |
| 2026-05-08 | Westend S.A. | 175.16M | 39.40% |
| 2026-05-08 | Siren, L.L.C. | 42.77M | 9.60% |
| 2026-05-08 | Invus Global Management, LLC | 42.77M | 9.60% |
| 2026-05-08 | Invus Public Equities Advisors, LLC | 7.36M | 1.70% |
| 2026-05-08 | Invus Public Equities, L.P. | 7.36M | 1.70% |
| 2026-05-08 | Ulys, L.L.C. | 6.99M | 1.60% |
| 2026-05-08 | Invus US Partners LLC | 5.45M | 1.20% |
| 2026-05-08 | Invus, L.P. | 42.77M | 9.60% |
| 2026-05-08 | Invus Advisors, L.L.C. | 42.77M | 9.60% |
| 2026-05-08 | Artal Group S.A. | 175.16M | 39.40% |
| 2026-05-08 | Artal International Management S.A. | 175.16M | 39.40% |
| 2026-05-08 | Artal International S.C.A. | 175.16M | 39.40% |
| 2026-05-08 | Artal Participations S.a r.l. | 175.16M | 39.40% |
| 2026-02-02 | Invus US Partners LLC | 5.45M | 1.30% |
| 2026-02-02 | Mr. Amaury Wittouck | 154.73M | 36.20% |
| 2026-02-02 | Stichting Administratiekantoor Westend | 154.73M | 36.20% |
| 2026-02-02 | Westend S.A. | 154.73M | 36.20% |
| 2026-02-02 | Artal Group S.A. | 154.73M | 36.20% |
| 2026-02-02 | Artal International Management S.A. | 154.73M | 36.20% |
| 2026-02-02 | Artal International S.C.A. | 154.73M | 36.20% |
| 2026-02-02 | Artal Participations S.a r.l. | 154.73M | 36.20% |
| 2026-02-02 | Mr. Raymond Debbane | 51.22M | 12.00% |
| 2026-02-02 | Ulys, L.L.C. | 6.99M | 1.60% |
| 2026-02-02 | Invus Public Equities Advisors, LLC | 7.36M | 1.70% |
| 2026-02-02 | Avicenna Life Sci Master GP LLC | 1.54M | 0.40% |
| 2026-02-02 | Avicenna Life Sci Master Fund LP | 1.54M | 0.40% |
| 2026-02-02 | Siren, L.L.C. | 42.77M | 10.00% |
| 2026-02-02 | Invus Global Management, LLC | 42.77M | 10.00% |
| 2026-02-02 | Invus, L.P. | 42.77M | 10.00% |
| 2026-02-02 | Invus Advisors, L.L.C. | 42.77M | 10.00% |
| 2026-02-02 | Invus Public Equities, L.P. | 7.36M | 1.70% |
| 2025-07-08 | FMR LLC | 38.14M | 10.50% |
| 2025-05-12 | FMR LLC | 34.54M | 9.60% |
| 2024-07-10 | Abigail P. Johnson | 38.69M | 10.70% |
| 2024-07-10 | FMR LLC | 38.69M | 10.70% |
| 2022-02-14 | Biotechnology Value Fund, L.P. | 7.56M | 5.10% |
| 2020-12-21 | BVF I GP LLC | 5.79M | 4.10% |
| 2020-12-21 | Biotechnology Value Fund II, L.P. | 4.26M | 3.00% |
| 2020-12-21 | BVF II GP LLC | 4.26M | 3.00% |
| 2020-12-21 | BVF GP HOLDINGS LLC | 10.05M | 7.10% |
| 2020-12-21 | BVF Partners OS Ltd. | 704.35K | 1.00% |
| 2020-12-21 | Biotechnology Value Trading Fund OS LP | 704.35K | 1.00% |
| 2020-12-21 | Mark N. Lampert | 10.96M | 7.80% |
| 2020-12-21 | Biotechnology Value Fund, L.P. | 5.79M | 4.10% |
| 2020-12-21 | BVF Inc. | 10.96M | 7.80% |
| 2020-12-21 | BVF Partners L.P. | 10.96M | 7.80% |
| 2019-02-13 | 98-0186363 | 98.0 | 4.01% |
| 2018-02-13 | 98-0186363 | 98.0 | 5.30% |
| 2017-02-14 | Fidelity Growth Company Fund | 6.48M | 6.23% |
| 2017-02-14 | Abigail P. Johnson | 15.61M | 15.00% |
| 2017-02-14 | FMR LLC | 15.61M | 15.00% |
| 2017-01-20 | 98-0186363 | 98.0 | 5.02% |
| 2016-02-16 | 98-0186363 | 98.0 | 10.06% |
| 2010-04-12 | Edward C. Johnson 3d | 34.24M | 13.00% |
| 2010-04-12 | FMR LLC | 34.24M | 13.00% |
| 2010-02-11 | 52-0556948 | 8.96M | 5.00% |
| 2007-06-27 | (. | 16.5M | 16.10% |
| 2007-06-27 | Raymond Debbane | 20.39M | 19.90% |
| 2007-06-27 | (. | 20.39M | 19.90% |
| 2007-06-27 | (. | 3.89M | 4.53% |
| 2007-06-27 | (. | 3.89M | 4.53% |
| 2007-06-27 | (. | 16.5M | 16.10% |
| 2007-06-25 | Symphony Capital Partners, L.P. | 4.95M | 5.80% |
| 2007-06-25 | Harri V. Taranto | 5.33M | 6.20% |
| 2007-06-25 | Neil J. Sandler | 5.33M | 6.20% |
| 2007-06-25 | Mark Kessel | 5.33M | 6.20% |
| 2007-06-25 | Symphony Strategic Partners, LLC | 374.87K | 0.40% |
| 2007-06-25 | Symphony GP, LLC | 4.95M | 5.80% |
| 2007-06-25 | Symphony Capital GP, L.P. | 4.95M | 5.80% |
| 2006-03-09 | Invus Public Equities, L.P. 98-0420215 | 3.3M | 5.11% |
| 2006-03-09 | Invus Public Equities Advisors, L.L.C. 98-0420201 | 3.3M | 5.11% |
| 2006-03-09 | Ulys, L.L.C. 83-0359139 | 3.3M | 5.11% |
| 2006-03-09 | Raymond Debbane | 3.3M | 5.11% |
| 2005-02-11 | Arthur T. Sands, M.D., Ph.D. | 3.8M | 5.70% |
| 2003-02-13 | (: | 3.46M | 6.30% |
LXRX Enterprise Value History
Annual
| Date | Stock Price | Shares Outstanding | Market Cap | Cash & Equivalents | Total Debt | Enterprise Value |
|---|---|---|---|---|---|---|
| 2025-12-31 | $1.15 | 363.05M | $417.51M | $34.33M | $62.24M | $445.42M |
| 2024-12-31 | $0.74 | 320.03M | $236.34M | $66.66M | $108.4M | $278.08M |
| 2023-12-31 | $1.53 | 221.13M | $338.33M | $22.46M | $106.06M | $421.93M |
| 2022-12-31 | $1.91 | 165.73M | $316.55M | $46.34M | $55.29M | $325.5M |
| 2021-12-31 | $3.94 | 145.65M | $573.87M | $64.06M | $2.28M | $512.08M |
| 2020-12-31 | $3.42 | 110.84M | $379.08M | $126.26M | $12.81M | $265.62M |
| 2019-12-31 | $4.15 | 106.22M | $440.8M | $36.11M | $246.84M | $651.53M |
| 2018-12-31 | $6.64 | 105.74M | $702.14M | $160.05M | $245M | $787.09M |
| 2017-12-31 | $9.88 | 105.12M | $1.04B | $310.79M | $245.67M | $973.49M |
| 2016-12-31 | $13.83 | 103.86M | $1.44B | $346.5M | $101.45M | $1.19B |
Quarterly
| Date | Stock Price | Shares Outstanding | Market Cap | Cash & Equivalents | Total Debt | Enterprise Value |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1.56 | 400.24M | $624.37M | $38.09M | $57.71M | $643.99M |
| 2025-12-31 | $1.15 | 363.43M | $417.94M | $34.33M | $62.24M | $445.85M |
| 2025-09-30 | $1.35 | 363.4M | $490.59M | $49.66M | $64.94M | $505.88M |
| 2025-06-30 | $0.95 | 363.29M | $343.57M | $21.36M | $61.45M | $383.65M |
| 2025-03-31 | $0.46 | 362.07M | $166.84M | $62.89M | $106.26M | $210.22M |
| 2024-12-31 | $0.74 | 361.49M | $266.96M | $66.66M | $108.4M | $308.7M |
| 2024-09-30 | $1.57 | 361.49M | $567.54M | $34.55M | $105.87M | $638.86M |
| 2024-06-30 | $1.68 | 310.84M | $522.2M | $35.62M | $105.68M | $592.26M |
| 2024-03-31 | $2.28 | 245.39M | $559.49M | $96.49M | $106.24M | $569.24M |
| 2023-12-31 | $1.53 | 244.92M | $374.74M | $22.46M | $106.06M | $458.33M |
| 2023-09-30 | $1.09 | 244.92M | $266.97M | $21.12M | $106M | $351.85M |
| 2023-06-30 | $2.29 | 204.78M | $468.95M | $102.27M | $105.54M | $472.23M |